Psychosocial Services/Management of Depression


Antidepressant

Suggested target dosage range

Common side effects and cautions

Bupropion

200–400 mg divided (or bupropion extended release once daily)

Anxiety, agitation, headache, nausea, insomnia, seizures (rare)

Citalopram

20–40 mg daily

Nausea, headache, diarrhea, sedation, anxiety, sexual dysfunction. May cause decreased platelet aggregation, hyponatremia. Risk of QTc prolongation with dosages above 40 mg/day

Duloxetine

60–120 mg daily

Nausea or GI upset, headache, diarrhea, sedation, anxiety, sweating. May cause decreased platelet aggregation, hyponatremia

Escitalopram

10–20 mg daily

Similar to citalopram. Lower risk of QTc prolongation

Fluoxetine

20–80 mg daily

Similar to citalopram. Strong cytochrome P450 2D6 inhibition

Mirtazapine

15–45 mg daily

Sedation, orthostasis, dry mouth, weight gain, agranulocytosis/neutropenia (rare)

Paroxetine

20–40 mg daily

Similar to citalopram, sedation, weight gain. Strong cytochrome P450 2D6 inhibition

Psychostimulants, e.g., methylphenidate

5–30 mg divided

Insomnia, anxiety, agitation, tremor

Sertraline

50–200 mg daily

Similar to citalopram. Mild cytochrome P450 2D6 inhibition

Tricyclic antidepressants, e.g., nortriptyline

50–150 mg daily

Sedation, orthostatic hypotension, anticholinergic effects, arrhythmia, delirium

Venlafaxine extended release

150–300 mg daily

Similar to duloxetine, hypertension at higher dosages



Concomitant use of serotonergic agents with metoclopramide may increase risk for extrapyramidal reactions and neuroleptic malignant syndrome, and use with opioids such as fentanyl can increase risk of serotonin syndrome. Psychostimulants such as methylphenidate and dextroamphetamine can be an effective initial treatment when significant psychomotor retardation and fatigue are present, and more rapid activation, e.g., to promote treatment engagement, exercise, and nutrition, is needed while awaiting the benefits of antidepressants.

While antidepressants are generally well tolerated in patients with cancer, certain potential side effects warrant particular attention. Drug-induced neutropenia has been reported with some antidepressants, such as tricyclics, trazodone, and mirtazapine; it can be particularly problematic in patients undergoing chemotherapy and usually becomes apparent after 1 or 2 weeks of exposure. The severity of neutropenia that develops depends upon the dose and the duration of medication exposure. Antidepressants with highly potent serotonin reuptake inhibition (e.g., fluoxetine, paroxetine, and sertraline) have been associated with abnormal bleeding and altered platelet function. Interactions between antidepressants and antineoplastic agents that are mediated by CYP450 isoenzymes (particularly 3A4) can potentially compromise the effectiveness of cancer treatments or increase their toxicity [41]. Citalopram, escitalopram, venlafaxine, and mirtazapine are among the least likely to inhibit CYP450 metabolism.



4.3.3 Psychotherapeutic Interventions


Literature on the overall efficacy of psychological interventions in reducing clinical depression in patients with cancer is limited. There are few high-quality randomized controlled trials (RCTs) of interventions in patients with cancer with clinical depression specified as an outcome and measured using validated tools [5, 42]. Additionally, there is a lack of clarity in defining “psychological interventions” in the cancer literature [43]. In a systematic review of RCTs for depression in adult patients with cancer, Walker et al. found only eight published manuscripts (describing seven trials) that met inclusion criteria for the analysis. Only one was a trial of psychotherapy, which found that behavioral activation and problem solving were both effective in treating depression in patients with breast cancer [5].

While psychotherapeutic and pharmacologic interventions have been shown to be efficacious for depression in some studies, the effectiveness and potential harms of different treatment approaches for depression in cancer patients are largely unknown, underscoring the need for more comparative effectiveness studies [5, 37]. A common call is for improved quality of study design and reporting, clear definition of clinically defined and measured end points, and unbiased reporting of results.

Research supporting various psychotherapeutic interventions in specific groups of cancer patients has examined a variety of outcomes. In a systematic review of interventions for patients with gastrointestinal cancers, interventions including various types of psychotherapy as well as exercise and pharmacologic interventions were generally found to be effective in reducing physical and psychosocial symptoms and improving quality of life [44]. In patients with colorectal cancers, various interventions were found to reduce length of hospital stay, days to stoma proficiency, symptoms of anxiety and depression, and quality of life [45]. In patients with prostate cancer, psychotherapeutic interventions have been found to improve the quality-of-life outcomes and increases in knowledge, but the clinical significance of these benefits is unclear [46].

The overall aim of psychotherapy in the oncology setting is to help patients improve coping strategies and promote adjustment to cancer diagnosis and treatment [37]. Other goals of therapy include reduction of distress, improvement of problem-solving skills, assistance in finding other sources of support, and reshaping negative or harmful thoughts. Additional benefits can be drawn from emotional support from the provider. Common therapies used with patients with cancer include supportive-expressive therapy, various types of cognitive behavioral therapy (CBT; including cognitive behavioral stress management and problem-solving therapy), and psychoeducational interventions.

Supportive, cognitive behavioral, and family or couples therapy are well supported by RCTs, reviews, and meta-analyses to be effective in reducing distress and improving quality of life in patients with cancer [4, 6]. In a meta-analysis of the efficacy of interventions for depressive symptoms in adults with cancer, Hart et al. evaluated ten RCTs with 1362 participants with mixed cancer types [4]. The authors found that five psychotherapeutic and four pharmacologic interventions were superior to control conditions for reducing depressive symptoms in adults with cancer (effect size d = .42). Interventions that were selected for elevated distress had larger effect sizes than those that did not select for elevated distress [4]. A meta-analysis of psychotherapeutic interventions targeting cognitive dysfunction in patients with various cancers showed no evidence of effect for reduced cognitive complaints but good support for improved quality of life [47]. Similarly, a systematic review of information provision and needs in patients with various cancers found that patients who were most satisfied had fulfilled information needs and experienced fewer information barriers, reported better health-related quality of life, and had less anxiety and depression; however, the authors found that reports of successful psychoeducational interventions aimed at improving information provision for patients are lacking [48].

One of the most effective behavioral interventions for patients with cancer may be promotion of physical activity. Exercise has been associated with improvements in physical and psychological function and has the added benefit of improving body image and health-related quality of life in patients with cancer [49, 50]. Across cancer types, exercise may have beneficial effects over time on fatigue and physical and social functioning. The authors found that positive effects of exercise interventions are more pronounced with moderate- or vigorous-intensity vs. mild-intensity exercise programs but concluded that further research is needed to determine how best to sustain positive effects of exercise over time and the essential attributes of exercise (mode, intensity, frequency, duration, timing) according to cancer type and treatment [51].

It may be particularly important to treat depression in the palliative care setting. There is little evidence supporting specific therapies in palliative care settings, but medications, CBT, problem-solving therapy, mindfulness techniques, and supportive therapies may all be helpful [20]. There is also growing evidence that quality palliative care itself may have significant psychosocial benefits. Early palliative care in patients with metastatic non-small cell lung cancer resulted in improved quality of life and less depression than in controls who received standard oncologic care alone. Patients in the early palliative care group had less aggressive end-of-life care but had longer survival [52].


4.3.4 Other Support Services


Patients and caregivers may experience a decline in emotional well-being, including an increase in depression, when barriers to treatment are not addressed and access to treatment or treatment engagement is impeded. Oncology social workers are often part of the multidisciplinary oncology team and can help manage the emotional, social, and concrete needs of patients, families, and caregivers. Social workers can provide navigational support and advocacy within complex medical systems, identify psychosocial or situational issues that may impair a patients’ ability to engage in treatment, and help to coordinate referrals to other supportive services, such as psychiatry, psychology, chaplaincy, palliative care, and support groups. They may also provide direct counseling and emotional support to patients and family members on issues including grief and loss, communication with family/couples and medical providers, parenting and family concerns, substance use and co-occurring disorders, medical-legal documents, and practical issues such as transportation and financial assistance.

With social workers often being co-located within an oncology treatment setting, they can routinely connect with patients in person or by phone to provide information or support, such as following significant medical appointments where they may have learned of disease progression or a recurrence. In this capacity, they are in a good position to initially screen and identify patients who are in high distress and engage them in treatment [53].


4.3.5 Working with Families


There are 4.6 million Americans who care for someone with cancer at home [54]. A diagnosis of cancer can be overwhelming for both patients and family members, resulting in many lifestyle and role changes. While assessing the impact of cancer and treatment on the family, it is helpful to understand the patient’s and family’s baseline strengths and difficulties, as preexisting psychosocial and mental health issues may be exacerbated by a cancer diagnosis.

Psychosocial care that supports patients and family members in establishing routine pleasant activities and rituals, re-establishing roles, and creating family time for communication and other activities can ease the burden of cancer and result in improved patient and family emotional and mental health [55]. Studies with non-cancer patients suggest that the presence of effective family caregivers can increase treatment adherence and improve overall care. For example, caregivers increase the probability of adherence to medication regimens, exercise protocols, and dietary recommendations, thus potentially diminishing the frequency and duration of hospitalizations. It is important to recognize, however, that a caregiver’s negative emotional state, cognitive and physical impairments (including fatigue), and low literacy can impede their ability to accurately manage patients’ medications [56].

A recent review of meta-analyses indicates that stress in caregivers can lead to psychological changes, sleep disturbances, and changes in physical health, immune function, and financial well-being. The authors note that when the patient and caregiver dyad is collectively treated, well-being of both parties is improved [57]. Research-tested interventions delivered to caregivers of patients with cancer have demonstrated reductions in many negative effects and improvements in caregivers’ coping skills, knowledge, and quality of life. These interventions may also reduce patients’ symptoms, lower mortality, and enhance patients’ physical and mental health [57]. Most of the published studies on interventions for caregivers are psychoeducational in nature, providing information on helping to manage the patient’s physical and emotional care. Other interventions focus on skills training (e.g., developing coping skills or training on couples’ communication strategies) or therapeutic counseling. Although these studies tended to have small to moderate effect sizes, they consistently demonstrated improvements in both patient and caregiver physical and mental health outcomes [57]. Depressed mood in spouses of patients with breast cancer has been shown to have a negative impact on the patient’s own functioning and well-being. Factors identified as risks for elevated depression in spouses of women with breast cancer include older age, less education, more recent marriage, elevated fears regarding their wife’s well-being, worry about their job performance, uncertainty about the future, and poorer marital adjustment [58]. It is critical to attend to modifiable risk factors in spouses and caregivers of all cancer patients, as it is likely that earlier intervention and support will benefit the family member and the patient themselves.


4.3.6 Collaborative Care



4.3.6.1 Background


The Chronic Care Model, [59] which is an approach to integrated, patient-centered care of chronic illness, has been shown to improve clinical outcomes, processes of care, and quality of life in patients with chronic conditions such as asthma, congestive heart failure, diabetes, and depression. Key elements include the use of explicit plans and protocols; practice reorganization to meet the needs of patients who require more time, a broad array of resources, and closer follow-up; systematic attention to the information and behavioral needs of patients; ready access to necessary expertise; and supportive information systems.

A coherent system of supportive care is needed to efficiently target patient need as well as integrate with both oncology and primary care services. Use of navigators and care managers to coordinate care across services can eliminate fragmentation and increase efficiency. Recently, the Chronic Care Model has been specifically adapted as a model of quality cancer care. It emphasizes the need for an accountable practice team or care manager to ensure that the cancer care and psychosocial care are coordinated across the different phases of cancer and modalities of care [60].

The Chronic Care Model has been adapted to improve the management of depression and other mental disorders, leading to the development of collaborative care models. Collaborative care, which goes beyond merely “co-locating” psychosocial providers in cancer settings, is a practical way of delivering effective and integrated psychosocial oncology care. Core components of collaborative psychosocial oncology care include:

1.

Delivery system redesign using integration of a centralized care manager to link patients; oncology, primary care, and psychosocial care providers; and other clinics or community resources. This often involves redefinition of work roles for clinical and support staff (Table 4.2).


Table 4.2
Members and roles of the collaborative psychosocial oncology care team in treating depression

























Member

Roles

Care manager

Performs systematic follow-up clinical assessments to patients identified with depression. Links oncology team, consulting specialists, primary care provider, and support staff by enhancing communication. Motivates, activates, and engages the patient in depression treatment. Provides education to the patient and family around depression and other common comorbid conditions. Provides education to the oncology team regarding the nature and severity of depression and recommendations for management. Coordinates depression management plan with oncology team. Refers to community resources and follows up on referrals to increase rates of follow-through. Provides brief, evidence-based depression treatment (e.g., motivational interviewing for engagement, cognitive behavioral therapy, behavioral activation, problem solving, grief counseling)

Oncology team

Follows up on recommendations from the care manager and/or consulting psychiatrist/psychologist, including prescribing antidepressant medications under close guidance. Communicates any changes in patient depression levels to the care manager to facilitate the re-screening and follow-up process

Psychiatrist/psychologist

Provides supervision and weekly caseload review with care managers to recommend specific depression interventions. Identifies patients in need of more specialized consultation via the stepped care model and facilitates referral to the psychiatry/psychology service. Supports care managers and monitors for provider burnout. Provides regular training sessions to the care managers and oncology team to enhance provider education, particularly around medications and brief psychosocial treatments. Participates in institutional quality improvement initiatives and monitoring

Primary care provider

Communicates with the care manager and oncology team to provide patient history. Supports transition back into primary care after completion of active cancer treatment

Patient

Completes screeners and rating scales. Partners with treatment team in shared decision-making and implementing recommendations (including medications, counseling, behavioral strategies, and follow-up appointments) and tracking depression outcomes. Communicates any new concerns to the care manager and/or oncology team

 

2.

Systematic, population-based approach to identifying needs and measuring outcomes using validated treatment response measures.

 

3.

Electronic case registries to facilitate information flow and track critical clinical information for the caseload.

 

4.

Strategies to engage, educate, and motivate the patient (and family) and monitor and enhance treatment adherence.

 

5.

Brief, evidence-based, psychosocial treatments (e.g., problem solving, behavioral activation, cognitive behavioral therapy) provided by care managers.

 

6.

Regular team caseload review and supervision of care managers by mental health specialists, including consultation for treatment nonresponders.

 

7.

Stepped care management model providing intensified intervention to patients with inadequate clinical response.

 

Meta-analyses examining the effectiveness of collaborative care for depression in primary care have shown improved short- and long-term depression outcomes compared with standard care. Thota et al., in a meta-analysis of 69 trials, [61] showed robust evidence of effectiveness of collaborative care in improving depression symptoms, adherence and response to treatment, remission of symptoms, quality of life/functional status, and satisfaction with care. A systematic review of the economic efficiency of collaborative care for depression confirmed its cost-effectiveness and economic value [62]. Research has also shown that collaborative care programs that target both depression and pain can lead to greater improvements in both depression- and pain-related disability [63].

There is strong evidence that the collaborative care approach is adaptable across multiple mental health conditions, medical settings, and patient populations and provides a robust clinical and policy framework for care integration. A Cochrane review [64] of 79 RCTs of collaborative care for depression and anxiety, representing a wide variety of settings, participants, medical comorbidities, and treatment modalities, found that collaborative care increases the delivery of guideline-concordant care and is effective in improving both short- and long-term outcomes across a broad range of healthcare settings, including underserved minority populations. A meta-analysis of 57 trials [65] revealed significant effects of collaborative care across multiple disorders and care settings for clinical symptoms, mental and physical quality of life (QOL), and social role function, with no net increase in total healthcare costs.


4.3.6.2 Application of Collaborative Care in Oncology Settings


Because cancer centers are facing similar fiscal challenges as other healthcare systems, they must find ways to provide cost-efficient psychosocial care. While referral to community mental health providers for depression and other psychosocial problems remains an important option, many patient-, provider-, and system-level advantages exist for providing “in-house” psychosocial oncology services, when possible. For example, patients typically prefer to receive centralized healthcare, especially during intensive cancer treatment; providers benefit from comprehensive health records during complex treatment regimens; and care can be better coordinated within a single institution. These advantages, however, are counterbalanced against the costs of providing psychosocial care that is potentially resource intensive and often not revenue producing.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Feb 15, 2017 | Posted by in ONCOLOGY | Comments Off on Psychosocial Services/Management of Depression

Full access? Get Clinical Tree

Get Clinical Tree app for offline access